Victory Capital Management Inc. lifted its position in shares of DaVita Inc. (NYSE:DVA – Free Report) by 471.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,866 shares of the company’s stock after buying an additional 28,766 shares during the quarter. Victory Capital Management Inc.’s holdings in DaVita were worth $3,296,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. raised its stake in DaVita by 176.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 13,086 shares of the company’s stock valued at $1,315,000 after purchasing an additional 8,347 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in DaVita by 1.7% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 147,008 shares of the company’s stock valued at $14,770,000 after purchasing an additional 2,479 shares during the last quarter. Versor Investments LP acquired a new position in DaVita in the 2nd quarter valued at about $1,131,000. AE Wealth Management LLC raised its stake in DaVita by 907.2% in the 3rd quarter. AE Wealth Management LLC now owns 40,328 shares of the company’s stock valued at $3,812,000 after purchasing an additional 36,324 shares during the last quarter. Finally, IFM Investors Pty Ltd raised its stake in DaVita by 78.1% in the 3rd quarter. IFM Investors Pty Ltd now owns 21,115 shares of the company’s stock valued at $1,996,000 after purchasing an additional 9,261 shares during the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.
DaVita Stock Down 0.7 %
DVA opened at $110.82 on Friday. The company has a debt-to-equity ratio of 6.01, a current ratio of 1.24 and a quick ratio of 1.19. The stock has a market capitalization of $10.12 billion, a price-to-earnings ratio of 17.00, a price-to-earnings-growth ratio of 0.77 and a beta of 1.00. The business has a 50-day moving average of $106.87 and a two-hundred day moving average of $98.81. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $116.97.
Analyst Ratings Changes
Several brokerages recently weighed in on DVA. UBS Group cut their target price on shares of DaVita from $142.00 to $113.00 and set a “buy” rating for the company in a research note on Friday, November 17th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $102.67.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Five stocks we like better than DaVita
- Upcoming IPO Stock Lockup Period, Explained
- The 5 best small cap AI companies to buy now
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- What Do S&P 500 Stocks Tell Investors About the Market?
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.